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OBJECTIVE — To prospectively examine the association of depression with risks for ad-
vanced macrovascular and microvascular complications among patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS — A longitudinal cohort of 4,623 primary care
patients with type 2 diabetes was enrolled in 2000–2002 and followed through 2005–2007.
Advanced microvascular complications included blindness, end-stage renal disease, amputa-
tions, and renal failure deaths. Advanced macrovascular complications included myocardial
infarction, stroke, cardiovascular procedures, and deaths. Medical record review, ICD-9 diag-
nostic and procedural codes, and death certiﬁcate data were used to ascertain outcomes in the
5-yearfollow-up.Proportionalhazardmodelsanalyzedtheassociationbetweenbaselinedepres-
sion and risks of adverse outcomes.
RESULTS — After adjustment for prior complications and demographic, clinical, and diabe-
tes self-care variables, major depression was associated with signiﬁcantly higher risks of adverse
microvascular outcomes (hazard ratio 1.36 [95% CI 1.05–1.75]) and adverse macrovascular
outcomes (1.24 [1.0–1.54]).
CONCLUSIONS — Amongpeoplewithtype2diabetes,majordepressionisassociatedwith
an increased risk of clinically signiﬁcant microvascular and macrovascular complications over
theensuing5years,evenafteradjustingfordiabetesseverityandself-careactivities.Clinicaland
publichealthsigniﬁcanceoftheseﬁndingsrisesastheincidenceoftype2diabetessoars.Further
research is needed to clarify the underlying mechanisms for this association and to test inter-
ventionstoreducetheriskofdiabetescomplicationsamongpatientswithcomorbiddepression.
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D
epression is adversely associated
with diabetes, from incidence to
mortality(1–3).Comparedwithin-
dividuals with diabetes alone, those with
comorbid depression have increased dis-
ease burden, greater symptom severity,
increased work disability, and increased
medical services use (4–6). Comorbid
depression is also associated with sub-
stantially higher health care costs among
patients with a range of diabetes compli-
cations (7).
Both biologic and behavioral factors
may play a role in the relationship be-
tween depression and diabetes com-
plications. Depression and chronic psy-
chologicalstresscanactivatethehypotha-
lamic-pituitary-adrenal axis, stimulate
the sympathetic nervous system, increase
inﬂammatory and platelet aggregation re-
sponses, and contribute to poor diabetes
control (8). Poor glycemic control in-
creases the risk of diabetes complications
(9). Depression may also impair glycemic
control through negative effects on self-
care behaviors (adherence to diet, exer-
cise, checking blood glucose, and taking
medications as prescribed) (10–12).
The relationship between depression
and type 2 diabetes is bidirectional (1).
Individuals with depression, but no dia-
betes, are at higher risk for developing
diabetes at follow-up. Conversely, indi-
viduals with no depression, but receive
diabetes treatment, are at a higher risk for
developing depression at follow-up. For
example, patients with diabetes compli-
cations such as nephropathy requiring
hemodialysisorretinopathyandresulting
blindness face signiﬁcant impairment in
their daily lives. These daily stressors can
beoverwhelmingand,inturn,precipitate
or worsen depression.
A meta-analysis of 27 studies found a
signiﬁcant association between depres-
sion and a wide variety of diabetes com-
plications (neuropathy, retinopathy,
nephropathy, macrovascular complica-
tions, and sexual dysfunction) (13). The
conclusions that can be drawn from indi-
vidual studies are limited given their rel-
atively small samples, which included
patients with both type 1 and type 2 dia-
betes. While meta-analyses can combine
information to overcome problems with
small samples in individual studies, mea-
surement problems remain a limitation of
these studies. The diabetes complications
considered included both mild and ad-
vanced pathophysiologic changes (e.g.,
both microalbuminuria and stroke) and
both self-reported symptoms (e.g., pain
severity or impotence) and objectively
documented disorders (e.g., retinopathy
or glomerular ﬁltration rate). In addition,
depression assessment often used symp-
tom-severity scales and lacked diagnostic
measures. The greatest limitation of these
studies was their cross-sectional design.
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whether patients are depressed because
theyhavedisablingandworrisomediabe-
tes complications or whether having
depression could actually precede occur-
rence of severe and clinically signiﬁcant
diabetes complications.
In the only large-scale prospective
study,Blacketal.(2)foundinasampleof
2,830 elderly Mexican Americans with
type 2 diabetes (aged 65 years) that
comorbid depression at baseline was
associated with an increased risk of mac-
rovascular and microvascular complica-
tions over a 7-year period. This study was
limited to an elderly population from one
ethnic group, and presence of diabetes
and complications were based on patient
self-report. The analyses also did not ac-
count for potential clinical confounders
ormediatorssuchasglycemiccontrol,se-
verity of medical comorbidity, or health
habits. This prospective study investi-
gates whether there is a link between de-
pression and subsequent development of
clinically signiﬁcant diabetes complica-
tions in a large cohort of primary care pa-
tients. We aim to close three gaps in prior
research. First, we examined only ad-
vanced and medical chart–veriﬁable
microvascular and macrovascular com-
plications. Second, we adjusted for clini-
cal confounders and variables that may
mediate the relationship between depres-
sion and diabetes. Third, we assessed de-
pression using a measure that has been
validated against the gold standard diag-
nosticinterviewforaclinicalaffectivedis-
order (14).
RESEARCH DESIGN AND
METHODS — Group Health is a mixed-
model prepaid health plan serving ap-
proximately half a million members in
Washington state. Most Group Health
members receive medical services within
the integrated group practice, which in-
cludes 30 primary care clinics in western
Washington. The Group Health enroll-
ment is demographically similar to the
area population. All study procedures
were approved by institutional review
boards at Group Health and the Univer-
sity of Washington. This research was
supportedbygrantsfromtheNationalIn-
stitutes of Health (MH 073686).
The cohort for this longitudinal pro-
spective study, the Pathways Epidemio-
logic Follow-Up Study, was initially
sampled between 2000 and 2002 from
adults in the Group Health diabetes reg-
istry who received care at any of nine pri-
mary care clinics in the Seattle/Puget
Sound area selected because of the socio-
economic, racial, and ethnic diversity of
the patients they serve (15). The Group
Health diabetes registry includes all
Group Health members meeting any of
thefollowingeligibilitycriteriainthepre-
ceding 12 months: ﬁlled prescription for
insulin or an oral hypoglycemic agent,
two fasting plasma glucose levels 126
mg/dl, two random plasma glucose levels
200 mg/dl, two outpatient diagnoses of
diabetes, or any inpatient diagnosis of di-
abetes (15).
Surveys were mailed to 9,063 poten-
tially eligible patients, but 1,222 patients
were later found to be ineligible due to
reasons such as death, disenrollment, er-
roneous diagnosis of diabetes, or cogni-
tive impairment. Among 7,841 eligible
patients,4,839subjects(61.7%ofeligible
patients) returned the baseline question-
naire. Patients with type 1 diabetes (n 
216) were excluded, and 4,623 patients
with type 2 diabetes participated in the
study and comprised the original Path-
ways Epidemiologic Study cohort (16).
Pathways Epidemiologic Follow-Up
Study
Approximately 5 years after enrollment,
surviving members of the original cohort
of patients with type 2 diabetes were re-
contacted by mailed letter and follow-up
telephone call during 2005–2007. Con-
senting patients completed a 20-min tele-
phone interview and were asked for
permission to review their electronic and
paper medical records for information on
medical conditions. Waiver of consent to
review electronic and paper medical
records was approved by the human sub-
jects review committee for patients who
had died since enrollment in the cohort.
Assessment of clinical adverse
outcomes of diabetes
Usingmedicalrecordreview,ICD-9diag-
nostic and procedure code data, and
Washington state death certiﬁcate data,
we identiﬁed physician-diagnosed and
objectively documented macrovascular
and microvascular complications of dia-
betes, before baseline and during follow-
up. Microvascular complications included
end-stage renal disease (ESRD), low vision
or blindness, proliferative retinopathy or
photocoagulation procedures for diabe-
tes, foot ulcers, and amputations. Macro-
vascular complications included myo-
cardialinfarction,stroke,congestiveheart
failure (CHF), cardiovascular procedures
(percutaneous coronary artery interven-
tion, coronary artery bypass grafting, and
abdominal aortic aneurysm repair), and re-
vascularization of the lower extremity.
Deathsduetocoronary,cerebrovascular,or
peripheral arterial disease were include as
adverse macrovascular events, and deaths
due to ESRD were included as adverse mi-
crovascular events (3). The speciﬁc codes
and deﬁnitions for some of these adverse
diabetes outcomes were adopted from the
Women’s Health Initiative Study (17).
Please see the online appendix (available
at http://care.diabetesjournals.org/cgi/
content/full/dc09-1068/DC1)forcodesand
deﬁnitions used to identify these advanced
microvascular and macrovascular com-
plications.
Assessment of depression
The Patient Health Questionnaire-9
(PHQ-9) (18) was used to ascertain prob-
able major and minor depression at base-
line and follow-up. The PHQ-9 is a self-
report measure of depression symptoms
based on the American Psychiatric Asso-
ciation’s DSM-IV criteria for diagnosis of
depressive episode and has been found to
have an adequate sensitivity and high
speciﬁcityinrelationtoadiagnosisofma-
jor depression based on structured inter-
views (14,18). Following a standardized
method, each item was scored as positive
ifendorsedas“morethanhalfthetime”or
“nearly all the time,” and a diagnosis of
probable major depression required a
positive response to one of the two core
symptoms (depressed mood or loss of in-
terest) and a total of ﬁve positive symp-
toms for at least the last 2 weeks. Criteria
forprobableminordepressionrequiredat
least one core symptom (depressed mood
or loss of interest) and a total of two to
fourpositivesymptomsforatleastthelast
2 weeks.
Covariates: demographic, clinical,
and self-care characteristics
Potential confounders and mediators for
the association of depression and adverse
diabetes outcomes were selected a priori,
as covariates. We use the term “mediator”
to refer to variables that maybe on the
causal pathway in the relationship be-
tween depression and adverse events,
even though these mediators were as-
sessedatthesametimeasdepression.The
mailed survey included sociodemo-
graphic characteristics (age, sex, race, ed-
ucational attainment, and marital status),
diabetes duration, diabetes treatment
(none or diet, oral hypoglycemic only, or
Lin and Associates
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habitsfromtheSummaryofDiabetesSelf-
Care Questionnaire (smoking, physical
activity, diet, and blood glucose monitor-
ing) (19). Review of paper and electronic
medical records provided data on hyper-
tension and glycemic control (A1C).
Medical comorbidity was adjusted using
RxRISK, an empirically derived comor-
bidity measure based on medications pa-
tients take to manage chronic diseases
(20). This pharmacy-based comorbidity
adjustor has been found to yield good
prediction of hospitalization and mortal-
ity risks, in addition to total health care
costs. For this study, antidepressant and
hypoglycemic medications were not in-
cluded in the calculation of the RxRisk
score. Thus, the modiﬁed RxRisk score
shouldbeconsideredameasureofoverall
medical comorbidity other than depres-
sion or diabetes.
Statistical analyses
Weestimatedtheassociationbetweende-
pression and adverse outcomes using a
proportional hazards model (21). Be-
causethelengthoffollow-back(i.e.,years
of observation prior to baseline survey)
varied across individuals, analyses were
stratiﬁed by years of follow-back to ac-
countforvariationsintheamountofprior
data available. These models adjusted for
evidence of a prior history of adverse out-
comes. We also explored whether prior
adverse outcome history modiﬁed the ef-
fect of depression by including the inter-
action between depression and prior
adverseoutcomes.Sensitivityanalysesex-
aminedtheeffectofdepressionamongin-
dividuals with no indication of a prior
adverse outcome.
Proportional hazards models censor
individuals at the time of disenrollment,
deathfromothercauses(i.e.,attributedto
neither macrovascular nor microvascular
events), or the end of follow-up, which-
ever comes ﬁrst. We ﬁt four proportional
hazards models to each adverse outcome,
with each sequential model adding co-
variates. The ﬁrst model included only
baseline depression (major, minor, or
none) and an indicator of prior adverse
outcomes within the same class (micro-
vascular or macrovascular). The second
modeladdeddemographiccharacteristics
(age,sex,race,education,andmaritalsta-
tus).Thethirdmodeladdedclinicalchar-
acteristics at baseline (diabetes duration,
treatment type, RxRisk score, and hyper-
tension diagnosis). The fourth model
addedbaselineclinicalcharacteristicsand
health habits or self-care behaviors that
maybeaffectedbydepression(A1C,BMI,
smoking, and limited physical activity)
(10,16).
RESULTS— Figure 1 describes the
Pathways Epidemiologic and Follow-Up
Study sample recruitment. Among 4,623
patients with type 2 diabetes surveyed at
baseline, 12 (0.2%) were not eligible for
follow-upduetodisenrollmentorrefusal.
Among 4,611 sample eligible for the
5-year follow-up, data were collected for
3,922 (85.1%). We excluded participants
forthefollowingreasons:632(13.7%)re-
fused medical record review, 49 (1.0%)
were non-English speakers; 8 (0.2%) had
incomplete medical records (missing pa-
per chart), 12 (0.003%) had missing de-
pression status, and 199 (0.05%) had
missing demographic or clinical vari-
ables. This resulted in a ﬁnal sample size
of3,723patientsfortheanalysis.Another
3weremissingthedateofamicrovascular
outcome, and 39 were missing the date of
a macrovascular outcome and were un-
able to be included in the time-to-event
analysis.
The mean duration of follow-back
was (means  SD) 4.5  0.97 years.
Mean duration of follow-up was 20.8
years(rangingfrom6monthsto54years,
median 22 years, SD 10.9 years). Clinical
and demographic characteristics of the
Pathways Epidemiologic Follow-Up
Study cohort by baseline depression sta-
tus are summarized in Table 1. As re-
ported in a prior article, diabetic patients
with major depression were slightly
younger; had higher A1C, BMI, and med-
Figure 1—Pathways Epidemiologic Follow-Up sample recruitment.
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treated with insulin as compared with
those with no depression (16). The group
with major depression included a higher
proportion of women and current
smokers.
Adverse clinical outcomes of
diabetes
In this primary care type 2 diabetic co-
hort, 14.3% (533 of 3,723) of patients
had a clinically signiﬁcant microvascular
outcome during the follow-up period,
with 13.3% (394 of 2,965) of patients
with no depression (0.06 events per per-
son-year risk or 1 event per 15.8 person-
years risk), 18.7% (59 of 315) of patients
with minor depression (0.07 events per
person-year risk or 1 event per 13.6 per-
son-years risk), and 18.1% (80 of 443) of
patients with major depression (0.07
events per person-year risk or 1 event per
13.7 person-years risk) having a micro-
vascular event. Nearly a quarter (24.0%,
893 of 3,723) of patients had a clinically
signiﬁcant macrovascular outcome, with
23.7% (702 of 2,965) of patients with no
depression (0.03 events per person-year
risk or 1 event per 29.1 person-years
risk), 25.7% (81 of 315) of patients with
minor depression (0.05 events per
person-year risk or 1 event per 18.6
person-years risk), and 24.8% (110 of
443) of patients with major depression
(0.05 events per person-year risk or 1
eventper19.4person-yearsrisk)havinga
macrovascular event.
Table2showsestimatedhazardratios
for four models and the two types of se-
verecomplicationsinpatientswithminor
and major depression relative to the no
depression group. Major depression was
associated with a higher risk of both mi-
crovascular and macrovascular severe
complications across all four models. The
association between major depression
and severe adverse events strengthened
with addition of demographic covariates
Table 1—Baseline clinical and demographic characteristics by depression
Characteristics Total sample No depression
Minor
depression
Major
depression
n 3,723 2,965 315 443
Female 1,782 (47.9) 1,369 (46.2) 152 (48.3) 261 (58.9)
Nonwhite 726 (19.5) 555 (18.7) 81 (25.7) 90 (20.3)
High school education or less 919 (24.7) 696 (23.5) 101 (32.1) 122 (27.5)
Marital status single 1,245 (33.4) 941 (31.7) 112 (35.6) 192 (43.3)
Treatment
None or diet 947 (25.4) 798 (26.9) 71 (22.5) 78 (17.6)
Oral hypoglycemic agent only 1,746 (46.9) 1,422 (48.0) 143 (45.4) 181 (40.9)
Any insulin 1,030 (27.7) 745 (25.1) 101 (32.1) 184 (41.5)
Hypertension 2,392 (64.3) 1,887 (63.6) 217 (68.9) 288 (65.0)
Physical activity (1 day/week) 1,223 (32.9) 873 (29.4) 140 (44.4) 210 (47.4)
Any prior microvascular event 750 (20.2) 580 (19.6) 77 (24.4) 93 (21.0)
Any prior macrovascular event 1,042 (28.1) 788 (26.7) 108 (34.4) 146 (33.0)
Age 64.3  12.5 64.9  12.3 64.7  13.2) 60.1  13.0)
Diabetes duration (years) 8.8  8.4 8.6  8.4 10.2  9.2) 9.0  7.5)
A1C 7.8  1.6 7.7  1.5 7.9  1.6 8.1  1.7
BMI 31.8  7.2 31.2  6.8 32.3  7.0 35.0  9.1
RxRisk* 3,203  2,410 3,124  2,320 3,475  2,517 3,536  2,846
Data are n (%) or means  SD. *Medical comorbidity and expected cost in USD excluding diabetes and depression.
Table 2—Hazard ratios (95% CIs) for microvascular and macrovascular outcomes in patients with diabetes
Covariate adjustment
Microvascular Macrovascular
Minor depression Major depression Minor depression Major depression
Unadjusted 1.54 (1.16–2.03) 1.48 (1.16–1.88) 1.17 (0.92–1.47) 1.20 (0.98–1.47)
Adjusted for
Any prior event* 1.49 (1.13–1.97) 1.47 (1.15–1.87) 1.09 (0.86–1.37) 1.13 (0.92–1.38)
Any prior event and demographic
characteristics*† 1.48 (1.11–1.95) 1.67 (1.30–2.15) 1.11 (0.88–1.40) 1.49 (1.21–1.83)
Any prior event, demographic characteristics,
and clinical characteristics*†‡ 1.33 (1.00–1.76) 1.38 (1.07–1.77) 1.06 (0.83–1.33) 1.34 (1.08–1.65)
Any prior event, demographic characteristics,
clinical characteristics, and self-care and
diabetes control measures*†‡§ 1.31 (0.98–1.74) 1.36 (1.05–1.76) 1.00 (0.79–1.27) 1.25 (1.00–1.54)
Hazard ratios compare individuals with minor or major depression to those without depression at baseline and are based on models that match on years of
follow-back. *Any prior microvascular or macrovascular event. †Demographic characteristics at baseline, including age, sex, race, education, and marital
status.‡Clinical characteristics at baseline, including diabetes duration, treatment intensity, expected costs (RxRisk), and hypertension diagnosis. §Self-care
behaviors and disease control measures at baseline, including BMI, smoking, limited physical activity, and A1C.
Lin and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 2, FEBRUARY 2010 267andlessenedwithsubsequentadjustment
for clinical characteristics and, to a lesser
extent, potential mediators (i.e., health
habits and A1C levels).
We also found a signiﬁcant associa-
tion between minor depression and se-
veremicrovascularcomplicationsinthree
of four models. When potential clinical
mediators such as diabetes self-care and
A1C were added, this relationship be-
came nonsigniﬁcant. Results from sensi-
tivity analyses that examined the effect of
depression on microvascular and macro-
vascular complications only among indi-
viduals with no prior indication of these
complications produced very similar re-
sults that led to the same conclusions.
CONCLUSIONS — Among adults
with type 2 diabetes, we found that indi-
viduals with depression were at increased
risk of clinically signiﬁcant subsequent
micro- and- macrovascular complica-
tions, relative to individuals without de-
pressionatbaseline.Overa5-yearperiod,
patients with major depression and dia-
beteshada36%higherriskofdeveloping
advanced microvascular complications,
such as ESRD or blindness, and a 25%
higher risk of developing advanced mac-
rovascular complications, such as myo-
cardial infarction or stroke, compared
with diabetic patients without depres-
sion. The strength of the association be-
tween depression and risk of adverse
events generally increased with adjust-
ment for demographic variables but de-
creased with adjustment for clinical
characteristics. Adjustment for differ-
ences in health habits and glycemic con-
trol also reduced the association between
depression and macrovascular complica-
tions but did not change the association
between depression and microvascular
complications.
We observed similar patterns in esti-
mated associations between minor de-
pression and microvascular and
macrovascular complications, though the
estimated increase in risk associated with
minor depression was less than estimated
increases associated with major depres-
sion.Associationsbetweenminordepres-
sion and macrovascular complications
were not statistically signiﬁcant.
Biological, psychological, or behav-
ioralresponsestostressorsfacingpatients
with diabetes and comorbid depression
may all play important roles in the devel-
opment of adverse diabetes outcomes
(9,12,13,22). Interestingly, our data
showed that health habits such as physi-
cal inactivity and dietary factors (BMI)
increasedtheriskformacrovascularcom-
plications such as myocardial infarction
and stroke but had little effect on the as-
sociation of depression and development
of microvascular complications such as
blindness and ESRD. Results from a re-
cent study (23) demonstrated that physi-
cal inactivity played a signiﬁcant role in
the association of depressive symptoms
and subsequent cardiovascular events
among patients with coronary heart dis-
ease. However, more research is needed
to clarify the role of health risk behaviors
(smoking, physical activity, and diet) on
development of microvascular com-
plications.
Activation of the hypothalamic-
pituitary-adrenal axis (increased cortisol
secretion), the sympathetic nervous sys-
tem (increased catecholamine release),
proinﬂammatory and procoagulation re-
sponses (increased levels of cytokines or
platelet/endothelial cell adhesion mole-
cule-1) associated with depression may
provide a unifying pathophysiologic ex-
planationfordiseaseprogressionfoundin
patientswithtype2diabetesinthisstudy.
Depression has consistently been linked
to hypothalamic-pituitary-adrenal axis
dysregulation, sympathetic nervous sys-
tem activation, and proinﬂammatory and
procoagulation markers among patients
with coexisting cardiovascular disorders
(8,11). Perhaps these neuroendocrine
and inﬂammatory responses accompany-
ing depression also play similar roles in
the progression of microvascular and ma-
crovascular complications among pa-
tients with type 2 diabetes. Evidence that
depression is associated with more nega-
tive appraisals of insulin therapy could
also contribute to higher A1C levels and
increased risk for complications (24). De-
pressed patients would be less willing to
start insulin therapy than nondepressed
diabetic patients, thus delaying beneﬁts
from insulin treatment.
Limitations of this study include that
depression was only measured at one
pointintime.However,depressionrunsa
chronic or recurrent course among pa-
tients with coexisting diabetes. Approxi-
mately 75% of patients with depression
and diabetes (recruited from same co-
hort) had a lifetime history of chronic de-
pression lasting 2 years. Moreover,
80% of this cohort who met criteria for
major depression at the 5-year follow-up
also had major or minor depression at
baseline(22).Dataonthenumberofprior
depressive episodes were not collected to
permit ascertainment of whether recur-
rent depression versus an initial depres-
sive episode would have greater impact
on adverse outcomes. The study was
completedinonegeographicregionofthe
U.S., possibly limiting generalizability.
Strengths of this study include prospec-
tivefollow-upofalargesampleofprimary
care patients with type 2 diabetes; struc-
tured assessment of depression; use of
physician diagnoses, automated labora-
tory, pharmacy data, and chart review to
conﬁrm diagnosis; and the ability to con-
trol for important clinical covariates (e.g.,
prior adverse events medical comorbid-
ity, glycemic control) and diabetes
self-care activities (e.g., smoking and ex-
ercise). Finally, the focus on severe and
documented adverse diabetes outcomes
adds to the clinical signiﬁcance and pub-
lic health importance of these ﬁndings.
Major depression is associated with a
25% increased risk of advanced macro-
vascular complications and a 36% in-
creasedriskofmicrovascularcomplications
amongpatientswithtype2diabetes.Given
the rapidly increasing rates of type 2 dia-
betes, this increased risk has important
clinical and public health implications.
Thisworkdemonstratesaneedforfurther
research to test interventions that may re-
duce risks of diabetes complications
among patients with comorbid depres-
sionandtoexploreexplanatorybiological
mechanisms.
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